Verteporfin
Explore this paper's citation graph
Summary
PDT using verteporfin 6 mg/m2 activated with a 50 J/cm2 light dose, significantly reduced the loss of best-corrected visual acuity compared with placebo in patients with subfoveal CNV secondary to AMD over 12 months and/or 24 months.
- Type
- review
- Published
- 2006-01-01
- Cited by
- 27
- References
- 64
- OpenAlex
- https://openalex.org/W2070977431
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:33511031
Keywords
Verteporfin, Medicine, Macular degeneration, Choroidal neovascularization, Visual acuity
References
- Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
- GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES
- Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
- Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
- Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.
- Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
- Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
- Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
- Late-onset visual decline following successful treatment of subfoveal choroidal neovascularisation with photodynamic therapy
- Risk factors for age-related macular degeneration: Pooled findings from three continents.
- A functional profile of gene expression in ARPE-19 cells
- Photodynamic therapy for age-related macular degeneration: a candid appraisal.
- COMPARISON OF FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY FOR PATIENTS WITH CHOROIDAL NEOVASCULARIZATION AFTER PHOTODYNAMIC THERAPY
- Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
- Self-reported visual functioning and quality of life in age-related macular degeneration
- BDNF reduces the retinal toxicity of verteporfin photodynamic therapy.
- Clinical Pharmacokinetics of Verteporfin
- Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative.
- Influence of treatment parameters on selectivity of verteporfin therapy.
- Photodynamic therapy with verteporfin: observations on the introduction of a new treatment into clinical practice.
Cited by
- An experimental study of a modified dahuang zhechong pill on the--angiogenesis of RF/6A cells in vitro.
- Temoporfin (Foscan®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer †,‡
- Photodynamic therapy as an effective therapeutic approach in MAME models of triple negative and inflammatory breast cancers
- Phototriggerable Liposomes: Current Research and Future Perspectives
- PHOTODYNAMIC THERAPY FOR TAIWANESE PATIENTS WITH PATHOLOGIC MYOPIA:: A 2-Year Follow-Up
- Advances in ocular drug delivery: emphasis on the posterior segment
- Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness
- Quality of Life in Macular Degeneration Between Photodynamic Therapy and Pegaptanib Treatment Groups
- Ocular drug delivery systems: An overview
- Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications
- Semiconductor lasers vs LEDs in diagnostic and therapeutic medicine
- Singlet Oxygen Generation Using New Fluorene-based Photosensitizers Under One- And Two-photon Excitation
- The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 Kinases
- Modulation of Intracellular Oxygen Pressure by Dual‐Drug Nanoparticles to Enhance Photodynamic Therapy
- Trends and targets in antiviral phototherapy
- Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients
- Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems
- Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices
- Expression of T helper cytokines associated with MUC5AC secretion in eosinophil‐based endotypes of nasal polyps
- Role of yes‐associated protein in interleukin‐13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps
Related papers
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
- Photodynamic Therapy in Retinal Angiomatous Proliferation Stage I
- Modified Verteporfin Photodynamic Therapy (PDT), PDT Combined With Angiostatin In Vitro and In Vivo
- No-Dose Photodynamic Therapy Against half-dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationBrown DM, for the ANCHOR Study Group (Methodist Hosp, Houston; et al) N Engl J Med 355:1432–1444, 2006§
- Infrared Imaging of Classic Choroidal Neovascularisation Treated with Verteporfin Photodynamic Therapy (PDT)
- No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
- Verteporfin Therapy with Delayed Light Application for the Treatment of Occult Choroidal Neovascularization (CNV) in Age-Related Macular Degeneration (AMD)
- Efficacy of photodynamic therapy with verteporfin combined with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration
- Photosensitizers and Photodynamic Therapy: Verteporfin.